Using quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer

Darshil T. Jhaveri, Min Sik Kim, Elizabeth D. Thompson, Lanqing Huang, Rajni Sharma, Alison P. Klein, Lei Zheng, Dung T. Le, Daniel A. Laheru, Akhilesh Pandey, Elizabeth M. Jaffee, Robert A. Anders

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Pancreatic cancer is the fourth leading cause of cancerrelated deaths in the United States. Less than 6% of patients survive beyond the fifth year due to inadequate early diagnostics and ineffective treatment options. Our laboratory has developed an allogeneic, granulocyte-macrophage colonystimulating factor (GM-CSF)-secreting pancreatic cancer vaccine (GVAX) that has been tested in phase II clinical trials. Here, we employed a serum antibodies-based SILAC immunoprecipitation (SASI) approach to identify proteins that elicit an antibody response after vaccination. The SASI approach uses immunoprecipitation with patient-derived antibodies that is coupled to quantitative stable isotope-labeled amino acids in cell culture (SILAC). Using mass spectrometric analysis, we identified more than 150 different proteins that induce an antibody response after vaccination. The regulatory subunit 12A of protein phosphatase 1 (MYPT1 or PPP1R12A), regulatory subunit 8 of the 26S proteasome (PSMC5), and the transferrin receptor (TFRC) were shown to be pancreatic cancer-associated antigens recognized by postvaccination antibodies in the sera of patients with favorable disease-free survival after GVAX therapy. We further interrogated these proteins in over 80 GVAX-treated patients' pancreases and uniformly found a significant increase in the expression of MYPT1, PSMC5, and TFRC in neoplastic compared with nonneoplastic pancreatic ductal epithelium. We show that the novel SASI approach can identify antibody targets specifically expressed in patients with improved disease-free survival after cancer vaccine therapy. These targets need further validation to be considered as possible pancreatic cancer biomarkers.

Original languageEnglish (US)
Pages (from-to)225-233
Number of pages9
JournalCancer Immunology Research
Volume4
Issue number3
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Biomarkers
Immunoprecipitation
Antibodies
Cancer Vaccines
Transferrin Receptors
Serum
Isotopes
Disease-Free Survival
Antibody Formation
Vaccination
Cell Culture Techniques
Protein Phosphatase 1
Amino Acids
Active Immunotherapy
Phase II Clinical Trials
Proteins
Tumor Biomarkers
Granulocytes
Pancreas

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Jhaveri, D. T., Kim, M. S., Thompson, E. D., Huang, L., Sharma, R., Klein, A. P., ... Anders, R. A. (2016). Using quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer. Cancer Immunology Research, 4(3), 225-233. https://doi.org/10.1158/2326-6066.CIR-15-0200-T

Using quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer. / Jhaveri, Darshil T.; Kim, Min Sik; Thompson, Elizabeth D.; Huang, Lanqing; Sharma, Rajni; Klein, Alison P.; Zheng, Lei; Le, Dung T.; Laheru, Daniel A.; Pandey, Akhilesh; Jaffee, Elizabeth M.; Anders, Robert A.

In: Cancer Immunology Research, Vol. 4, No. 3, 01.03.2016, p. 225-233.

Research output: Contribution to journalArticle

Jhaveri, DT, Kim, MS, Thompson, ED, Huang, L, Sharma, R, Klein, AP, Zheng, L, Le, DT, Laheru, DA, Pandey, A, Jaffee, EM & Anders, RA 2016, 'Using quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer', Cancer Immunology Research, vol. 4, no. 3, pp. 225-233. https://doi.org/10.1158/2326-6066.CIR-15-0200-T
Jhaveri, Darshil T. ; Kim, Min Sik ; Thompson, Elizabeth D. ; Huang, Lanqing ; Sharma, Rajni ; Klein, Alison P. ; Zheng, Lei ; Le, Dung T. ; Laheru, Daniel A. ; Pandey, Akhilesh ; Jaffee, Elizabeth M. ; Anders, Robert A. / Using quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer. In: Cancer Immunology Research. 2016 ; Vol. 4, No. 3. pp. 225-233.
@article{3a20d683b538441c924bb70e278ca89e,
title = "Using quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer",
abstract = "Pancreatic cancer is the fourth leading cause of cancerrelated deaths in the United States. Less than 6{\%} of patients survive beyond the fifth year due to inadequate early diagnostics and ineffective treatment options. Our laboratory has developed an allogeneic, granulocyte-macrophage colonystimulating factor (GM-CSF)-secreting pancreatic cancer vaccine (GVAX) that has been tested in phase II clinical trials. Here, we employed a serum antibodies-based SILAC immunoprecipitation (SASI) approach to identify proteins that elicit an antibody response after vaccination. The SASI approach uses immunoprecipitation with patient-derived antibodies that is coupled to quantitative stable isotope-labeled amino acids in cell culture (SILAC). Using mass spectrometric analysis, we identified more than 150 different proteins that induce an antibody response after vaccination. The regulatory subunit 12A of protein phosphatase 1 (MYPT1 or PPP1R12A), regulatory subunit 8 of the 26S proteasome (PSMC5), and the transferrin receptor (TFRC) were shown to be pancreatic cancer-associated antigens recognized by postvaccination antibodies in the sera of patients with favorable disease-free survival after GVAX therapy. We further interrogated these proteins in over 80 GVAX-treated patients' pancreases and uniformly found a significant increase in the expression of MYPT1, PSMC5, and TFRC in neoplastic compared with nonneoplastic pancreatic ductal epithelium. We show that the novel SASI approach can identify antibody targets specifically expressed in patients with improved disease-free survival after cancer vaccine therapy. These targets need further validation to be considered as possible pancreatic cancer biomarkers.",
author = "Jhaveri, {Darshil T.} and Kim, {Min Sik} and Thompson, {Elizabeth D.} and Lanqing Huang and Rajni Sharma and Klein, {Alison P.} and Lei Zheng and Le, {Dung T.} and Laheru, {Daniel A.} and Akhilesh Pandey and Jaffee, {Elizabeth M.} and Anders, {Robert A.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1158/2326-6066.CIR-15-0200-T",
language = "English (US)",
volume = "4",
pages = "225--233",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Using quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer

AU - Jhaveri, Darshil T.

AU - Kim, Min Sik

AU - Thompson, Elizabeth D.

AU - Huang, Lanqing

AU - Sharma, Rajni

AU - Klein, Alison P.

AU - Zheng, Lei

AU - Le, Dung T.

AU - Laheru, Daniel A.

AU - Pandey, Akhilesh

AU - Jaffee, Elizabeth M.

AU - Anders, Robert A.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Pancreatic cancer is the fourth leading cause of cancerrelated deaths in the United States. Less than 6% of patients survive beyond the fifth year due to inadequate early diagnostics and ineffective treatment options. Our laboratory has developed an allogeneic, granulocyte-macrophage colonystimulating factor (GM-CSF)-secreting pancreatic cancer vaccine (GVAX) that has been tested in phase II clinical trials. Here, we employed a serum antibodies-based SILAC immunoprecipitation (SASI) approach to identify proteins that elicit an antibody response after vaccination. The SASI approach uses immunoprecipitation with patient-derived antibodies that is coupled to quantitative stable isotope-labeled amino acids in cell culture (SILAC). Using mass spectrometric analysis, we identified more than 150 different proteins that induce an antibody response after vaccination. The regulatory subunit 12A of protein phosphatase 1 (MYPT1 or PPP1R12A), regulatory subunit 8 of the 26S proteasome (PSMC5), and the transferrin receptor (TFRC) were shown to be pancreatic cancer-associated antigens recognized by postvaccination antibodies in the sera of patients with favorable disease-free survival after GVAX therapy. We further interrogated these proteins in over 80 GVAX-treated patients' pancreases and uniformly found a significant increase in the expression of MYPT1, PSMC5, and TFRC in neoplastic compared with nonneoplastic pancreatic ductal epithelium. We show that the novel SASI approach can identify antibody targets specifically expressed in patients with improved disease-free survival after cancer vaccine therapy. These targets need further validation to be considered as possible pancreatic cancer biomarkers.

AB - Pancreatic cancer is the fourth leading cause of cancerrelated deaths in the United States. Less than 6% of patients survive beyond the fifth year due to inadequate early diagnostics and ineffective treatment options. Our laboratory has developed an allogeneic, granulocyte-macrophage colonystimulating factor (GM-CSF)-secreting pancreatic cancer vaccine (GVAX) that has been tested in phase II clinical trials. Here, we employed a serum antibodies-based SILAC immunoprecipitation (SASI) approach to identify proteins that elicit an antibody response after vaccination. The SASI approach uses immunoprecipitation with patient-derived antibodies that is coupled to quantitative stable isotope-labeled amino acids in cell culture (SILAC). Using mass spectrometric analysis, we identified more than 150 different proteins that induce an antibody response after vaccination. The regulatory subunit 12A of protein phosphatase 1 (MYPT1 or PPP1R12A), regulatory subunit 8 of the 26S proteasome (PSMC5), and the transferrin receptor (TFRC) were shown to be pancreatic cancer-associated antigens recognized by postvaccination antibodies in the sera of patients with favorable disease-free survival after GVAX therapy. We further interrogated these proteins in over 80 GVAX-treated patients' pancreases and uniformly found a significant increase in the expression of MYPT1, PSMC5, and TFRC in neoplastic compared with nonneoplastic pancreatic ductal epithelium. We show that the novel SASI approach can identify antibody targets specifically expressed in patients with improved disease-free survival after cancer vaccine therapy. These targets need further validation to be considered as possible pancreatic cancer biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=84962040827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962040827&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-15-0200-T

DO - 10.1158/2326-6066.CIR-15-0200-T

M3 - Article

C2 - 26842750

AN - SCOPUS:84962040827

VL - 4

SP - 225

EP - 233

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 3

ER -